Company Information
- Type:
- Company
- Country:
- Japan
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 12 April 2012 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2024
Financial Information
Affiliated Subsidiaries
| Country | Company Name |
|---|---|
| Brazil | Daiichi Sankyo Brasil Farmaceutica |
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 29-Nov-2023 | 2023 Communication on Progress | Submitted |
| 23-Dec-2022 | Daiichi Sankyo Group Value Report 2022 | Advanced |
| 25-Dec-2021 | Communication on Progress | Advanced |
| 25-Dec-2020 | Daiichi Sankyo Group Value Report 2020 | Advanced |
| 26-Dec-2019 | Daiichi Sankyo Group Value Report 2019 | Advanced |
| 26-Dec-2018 | Daiichi Sankyo Group Value Report 2018 | Advanced |
| 26-Dec-2017 | Communication on Progress | Advanced |
| 26-Dec-2016 | Communication on Progress | Advanced |
| 24-Dec-2015 | Communication on Progress | Advanced |
| 25-Dec-2014 | Value Report 2014 | Advanced |
| 26-Dec-2013 | Value Report 2013 | Advanced |
| 25-Feb-2013 | Communication on Progress | Advanced |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.